Drug-Induced AKI: Mechanism Before Label

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

A drug name is not a mechanism. Link exposure, laboratory trajectory, urine findings, and the response to withdrawal or dose adjustment.

One exposure, several possible injury sites. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

One exposure, several possible injury sites. Arterioles — Hemodynamic change; Glomerulus — Consider protein and blood; Tubules — Cellular toxicity or crystals; Interstitium — Drug-associated inflammation. A creatinine rise can also reflect altered secretion. Reconstruct the exposure timeline. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Hemodynamic change

NSAIDs reduce prostaglandin-supported afferent dilation; ACE inhibitors and ARBs reduce efferent tone. Dehydration plus a diuretic and NSAID can turn reduced reserve into AKI. Examine perfusion and congestion before deciding whether fluids or a medicine hold is appropriate.

Tubular toxicity

Aminoglycosides, platinum chemotherapy, and excessive vancomycin exposure can injure tubules. Match the creatinine trend to dose, duration, drug levels, and other insults. Review the next dose immediately when clearance changes; do not wait for a scheduled weekly level.

Inflammation or crystals

Beta-lactams, PPIs, or NSAIDs can cause AIN; acyclovir and methotrexate can cause crystal injury. Stop or replace a plausible culprit and inspect urine. Hydration and urine-pH strategies are drug-specific, not universal crystal treatment.

Creatinine without equivalent GFR loss

Trimethoprim and cobicistat inhibit creatinine secretion. A small early rise with stable urine findings may reflect this effect; cystatin C can sometimes clarify discordance. Still evaluate genuine AKI if the rise progresses or potassium, urine output, or symptoms change.

Make the medication timeline visible

List prescription drugs, OTC analgesics, supplements, start dates, dose changes, and intercurrent illness. Distinguish a loading dose from maintenance dosing. In unstable AKI, a reported eGFR is not a steady-state clearance estimate.

Document the action and restart

Specify which medicine changed, the suspected mechanism, the alternative treatment, and the next creatinine/potassium check. Avoid permanently labeling beneficial RAAS or SGLT2 therapy as nephrotoxic solely because an expected hemodynamic dip occurred.

Supporting evidence

Continue learning